跳到正文
FDA 官方药品与生物制品信息·· 3 天前AI 评分53

FDA公布未来12个月仿制药产品特定指南新发布和修订计划

Upcoming Product-Specific Guidances for Generic Drug Product Development

AI 导读

FDA更新网页,列出未来12个月计划发布和修订的仿制药产品特定指南(PSG)清单。清单覆盖复杂与非复杂产品,并标注活性成分、给药途径、剂型、RLD申请号和计划发布月份。页面同时说明PSG按季度发布,修订分为关键、重大(体内或体外)、次要和编辑类,且计划时间可能变化。

正文 · 原文

Introduction

This web page provides information related to upcoming new and revised product-specific guidances (PSGs) to support the development and approval of safe and effective generic drug products, including the projected date of PSG publication, as a commitment under the Generic Drug User Fee Amendments of 2022 (GDUFA III). Upcoming PSGs for both complex and non-complex products that are planned to be published in the next 12 months are listed (these may be subject to change).

How often does FDA publish new and revised PSGs?

To support generic drug development and generic drug approval, FDA issues new and revised PSGs on a quarterly and as needed basis. These PSGs, including PSGs for both complex and non-complex generic drug products, when finalized, describe the agency's current thinking and expectations on how to develop generic drug products to specific reference listed drugs and are intended to assist the generic pharmaceutical industry with identifying the most appropriate methodology and evidence needed to support a specific generic drug’s approval. The published PSGs are announced in the Federal Register and made available to the public on FDA’s website.

What information is provided on this web page?

For new PSGs for generic drug products under development, this web page provides information on the active ingredient(s), the route of administration and dosage form, the reference listed drug (RLD) application number, and the planned publication month/year. In addition to this information, the list of PSGs for generic products under revision also includes the planned revision categories and brief descriptions. This web page describes FDA’s plans for issuing new and revised PSGs for both complex and non-complex generic drug products.

What do the different planned revision categories mean?

For revised PSGs, the planned revision categories briefly describe the nature of the anticipated revisions. Planned revision categories are defined as the following:

  • Critical revision: PSG revision includes additional bioequivalence (BE) study(ies) or evidence recommended that is necessary to establish BE and support FDA approval reflecting a change in the safety or effectiveness of the drug product. The critical revision has a potential impact on all ANDAs including the approved applications. Holders of approved applications are also expected to address the change in the safety or effectiveness of the drug product reflected in a critical revision to maintain its FDA approval.
  • Major revision: PSG revision includes additional BE study(ies) or evidence recommended that is necessary to establish BE and support FDA approval. Major revisions are categorized as in vivo major revisions and in vitro major revisions. Under GDUFA III, applicants or prospective applicants may request PSG teleconference if they have already commenced an in vivo bioequivalence study (i.e., the study protocol has been signed by the study sponsor and/or the contract research organization) to obtain Agency feedback on the potential impact of the new or revised PSG on its development program. Pre-submission or post-submission PSG meetings may be requested following feedback received at the PSG teleconference. Refer to GDUFA III Enhancements to the Pre-ANDA Program for additional details.
    • In vivo major revision: PSG revision includes additional in vivo bioequivalence study(ies) or evidence recommended to support FDA approval.
    • In vitro major revision: PSG revision includes additional in vitro bioequivalence study(ies) or evidence recommended to support FDA approval.
  • Minor revision: Any revision to a PSG that is not considered critical or major, including but not limited to when a PSG is to be revised to add an in vivo or in vitro BE option, to clarify recommended study design, to certain study(ies), to provide alternative (less burdensome) approaches to the currently recommended study(ies), to add information on newly approved strengths of the RLD, or to make other recommendations that would not generally result in additional recommended bioequivalence study(ies) or evidence by an ANDA applicant necessary to support FDA approval. Minor revisions include both in vivo and in vitro changes.
  • Editorial revision: PSG revision includes non-substantive changes such as updating external references, correcting grammatical issues, and streamlining the format of existing recommendations.

FDA will also provide specific information on the planned revision when such information is available for public release.

What is a complex generic drug product?

As described in the GDUFA III Commitment Letter and Classifying Approved New Drug Products and Drug-device Combination Products as Complex Products for Generic Drug Development Purposes (MAPP 5240.10), a complex generic drug product generally means the following:

  • A product with:
    • a complex active ingredient(s) (e.g., peptides, polymeric compounds, complex mixtures of APIs, naturally sourced ingredients)
    • a complex formulation (e.g., liposomes, colloids)
    • a complex route of delivery (e.g., locally acting drugs such as dermatological products and complex ophthalmological products and otic dosage forms that are formulated as suspensions, emulsions, or gels)
    • a complex dosage form (e.g., transdermals, metered dose inhalers, extended release injectables)
  • Complex drug-device combination products (e.g., auto injectors, metered dose inhalers); and
  • Other products where complexity or uncertainty concerning the approval pathway or possible alternative approaches would benefit from early scientific engagement.

How often does FDA update this web page?

This web page will be updated each time FDA issues a new quarterly PSG batch. Each update removes the published PSGs and adds any new PSG under development or revision. This advance notice will help generic drug companies to plan for their development of generic drug products.

New and Revised PSGs for Generic Drug Products

Below is the list of PSGs for both complex and non-complex generic drug products that FDA plans to issue and the list of PSGs that FDA plans to revise in the coming year. While this list reflects FDA’s effort to be transparent regarding current plans for developing PSGs for generic drug products, it should be noted that timing may be subject to change.

Planned New PSGs for Complex and Non-Complex
Generic Drug Products
Updated: November 19, 2026

Active Ingredient(s)Route of AdministrationDosage FormRLD or RS Application NumberProduct ComplexityPlanned PublicationUpdates
Adapalene; Benzoyl PeroxideTopicalGel220736Complex05/2027Planned publication date change to a later date
Amikacin SulfateInhalationSuspension, Liposomal207356ComplexBeyond 12 monthsNo change
Amlodipine BesylateOralTablet, Orally Disintegrating022026Non-Complex02/2027No change
AprepitantIntravenousEmulsion218754Complex05/2027Newly added
AripiprazoleOralTablet207202ComplexWithin the next 12 monthsNo change
Avobenzone; Ecamsule; OctocryleneTopicalCream021501, 021502Complex02/2027Newly added
Avobenzone; Ecamsule; Octocrylene; Titanium DioxideTopicalCream021471, 022009Complex02/2027Newly added
AztreonamInhalationFor Solution050814Complex05/2027No change
BaxdrostatOralTablet219878Non-Complex11/2027Newly added
Beclomethasone Dipropionate; Formoterol Fumarate; GlycopyrrolateInhalationAerosol, Metered219622Complex08/2027Newly added
Cefepime Hydrochloride; ZidebactamIntravenousPowder220787Non-Complex08/2027Newly added
Centanafadine HydrochlorideOralCapsule, Extended Release218145Non-Complex02/2027Newly added
Chlorhexidine GluconateTopicalCloth207964Non-Complex02/2027Newly added
Clobetasol PropionateTopicalCream209483ComplexWithin the next 12 monthsNo change
CopperIntrauterineSystem218201ComplexWithin the next 12 monthsPlanned publication date change to a later date
Copper HistidinateSubcutaneousPowder211241Non-Complex02/2027No change
Cyclobenzaprine HydrochlorideSublingualTablet219428Non-Complex02/2027Newly added
Dabigatran Etexilate MesylateOralPellets214358Non-Complex02/2027Planned publication date change to a later date
Desmopressin AcetateNasalSpray, Metered201656Complex08/2027Planned publication date change to a later date
DifamilastTopicalOintment219474Complex05/2027No change
Dihydroergotamine MesylateNasalPowder217901Complex02/2027Planned publication date change to a later date
Donidalorsen SodiumSubcutaneousSolution219407Complex02/2027No change
Doravirine; IslatravirOralTablet216964Non-Complex02/2027No change
Doxecitine; DoxribtimineOralFor Solution219792Non-Complex02/2027No change
Duloxetine HydrochlorideOralCapsule, Delayed Rel Pellets219131Non-ComplexWithin the next 12 monthsNo change
Elamipretide HydrochlorideSubcutaneousSolution215244Non-Complex02/2027Newly added
ElinzanetantOralCapsule219469Non-Complex02/2027No change
EnsitrelvirOralTablet220442Non-Complex11/2027Newly added
Estrogens, Conjugated; Medroxyprogesterone AcetateOral-28Tablet020527Complex02/2027Planned publication date change to a later date
EtripamilNasalSpray218571Complex02/2027No change
Ezetimibe; Rosuvastatin CalciumOralTablet213072Non-ComplexWithin the next 12 monthsNo change
FluconazoleOralFor Suspension020090Non-ComplexBeyond 12 monthsPlanned publication date change to a later date
Folic AcidOralSolutionFDA-2024-P-0422Non-ComplexWithin the next 12 monthsNo change
FurosemideSubcutaneousSolution217294Complex05/2027No change
GadoquatraneIntravenousSolution219627Non-Complex08/2027Newly added
GedatolisibIntravenousPowder219908Non-Complex11/2027Newly added
Glucagon HydrochlorideIntramuscular, Intravenous, SubcutaneousPowder201849Complex05/2027Newly added
Glucagon HydrochlorideIntramuscular, Intravenous, SubcutaneousPowder20918Complex05/2027Newly added
GlycopyrrolateInhalationSolution208437ComplexN/APublication no longer planned
Icotrokinra HydrochlorideOralTablet220149Non-Complex08/2027Newly added
IloprostInhalationSolution021779Non-ComplexWithin the next 12 monthsNo change
Leuprolide MesylateSubcutaneousEmulsion219745Complex05/2027Planned publication date change to a later date
Levamlodipine MaleateOralTablet212895Non-ComplexWithin the next 12 monthsNo change
Lidocaine; TetracaineTopicalPatch021623ComplexBeyond 12 monthsNo change
LinerixibatOralTablet220295Complex05/2027No change
Metformin Hydrochloride; SitagliptinOralTablet216743Non-Complex05/2027Newly added
MethocarbamolOralSuspension219843Non-Complex02/2027Newly added
MilsaperidoneOralTablet220358Non-Complex08/2027Newly added
Nafarelin AcetateNasalSpray, Metered019886Complex05/2027Planned publication date change to a later date
NicotineOralInhalant020714ComplexBeyond 12 monthsPlanned publication date change to a later date
Plozasiran SodiumSubcutaneousSolution219947Complex02/2027No change
RelacorilantOralCapsule220641Non-Complex08/2027Newly added
RiluzoleOralFilm212640Non-ComplexBeyond 12 monthsNo change
RizatriptanOralFilm205394Non-Complex05/2027No change
Rusfertide AcetateSubcutaneousPowder220605Non-Complex05/2027Newly added
Ruxolitinib PhosphateOralTablet, Extended Release217180Non-Complex02/2027Newly added
SevabertinibOralTablet219972Non-Complex02/2027No change
SonrotoclaxOralTablet220711Non-Complex11/2027Newly added
TadalafilOralTablet, Chewable218527Non-ComplexBeyond 12 monthsPlanned publication date change to a later date
TeduglutideSubcutaneousPowder203441Complex05/2027Newly added
TradipitantOralCapsule220152Non-Complex05/2027No change
TreprostinilInhalationSolution022387Complex05/2027No change
Treprostinil SodiumInhalationPowder213005Complex02/2027Planned publication date change to a later date
Trientine TetrahydrochlorideOralTablet215760Non-Complex02/2027Newly added
TrofinetideOralFor Solution219884Non-Complex05/2027Newly added
ZiftomenibOralCapsule220305Non-Complex02/2027No change
Zinc AcetateOralCapsule020458ComplexWithin the next 12 monthsNo change
ZoliflodacinOralFor Suspension219491Non-Complex05/2027Newly added
Zolpidem TartrateOralCapsule215721Non-Complex02/2027No change
Zolpidem TartrateOralTablet, Orally Disintegrating021412Non-Complex02/2027Newly added

Planned Revised PSGs for Complex and Non-Complex
Generic Drug Products
Updated: November 19, 2026

Active Ingredient(s)Route Of AdministrationDosage FormRLD or RS Application NumberPlanned Revision Category with DescriptionProduct ComplexityPlanned PublicationUpdates
Adapalene; Benzoyl PeroxideTopicalGel022320Minor Revision: Add information on newly approved (lower or middle) strengths of the RLDComplex05/2027Planned publication date change to a later date
Amantadine HydrochlorideOralCapsule, Extended Release208944Editorial Revision: Reorganize to include all strengths within a single PSGNon-Complex05/2027Newly added
Beclomethasone DipropionateNasalAerosol, Metered202813Minor Revision: Clarify in vitro study designComplex02/2027Newly added
CiclesonideNasalAerosol, Metered202129Minor Revision: Clarify in vitro study designComplex02/2027Newly added
Ciprofloxacin HydrochlorideOralTablet019537Major Revision: Add additional in vivo study design; Change in study design for in vivo BE study(ies)Non-Complex02/2027Newly added
ClomipheneOralTablet016131Minor Revision: Change in study design for in vivo BE studyNon-Complex02/2027Newly added
EstradiolVaginalCream086069Minor Revision: Add an in vitro BE optionComplex02/2027Newly added
Estrogens, conjugatedOralTablet004782Minor Revision: Add API sameness recommendations; Provide more details on product characterization Editorial Revison: Update the languageComplex02/2027No change
Ethinyl Estradiol; LevonorgestrelTransdermalSystem204017Editorial Revision: Update the language to match Orange BookComplex02/2027Newly added
EtonogestrelImplantationImplant021529Minor Revision: Clarify in vitro study designComplexWithin the next 12 monthsNo change
Exenatide SyntheticSubcutaneousSolution209210Minor Revision: Provide more details on product characterization Editoiral Revision: Update the languageComplexN/APublication no longer planned
Exenatide SyntheticSubcutaneousSolution022200Minor Revision: Provide more details on product characterization Editoiral Revision: Update the languageComplexN/APublication no longer planned
FluorouracilTopicalCream020985Minor Revision: Add an in vitro BE optionComplexBeyond 12 monthsNo change
Guanfacine HydrochlorideOralTablet019032Minor Revision: Add information on newly approved (lower or middle) strengths of the RLDNon-Complex05/2027Newly added
Leuprolide AcetateInjectionInjectable019732, 020011, 020263Minor Revision: Add recommendations for device comparisons; Provide more details on in vitro testing Editoiral Revision: Update the languageComplex02/2027Planned publication date change to a later date
Leuprolide AcetateInjectionInjectable020517, 020708Minor Revision: Add recommendations for device comparisons; Provide more details on in vitro testing Editoiral Revision: Update the languageComplex02/2027Planned publication date change to a later date
Leuprolide MesylateSubcutaneousEmlusion211488Minor Revision: Add an in vitro BE optionComplex05/2027Newly added
LinaclotideOralCapsule202811Editoral Revision: Correct typosComplex02/2027Newly added
Lutetium Lu 177 DotatateIntravenousSolution208700Editorial Revision: Update the language to match Orange BookComplex02/2027Planned publication date assigned
Maralixibat ChlorideOralTablet219485Minor Revision: Add an in vivo BE optionComplex02/2027Newly added
Metformin HydrochlorideOralFor Suspension, Extended Release212595Minor Revision: Remove recommendations on fasting BE study; Clarify in vitro study designNon-Complex02/2027Newly added
MirdametinibOralTablet219379Minor Revision: Add information on newly approved (lower or middle) strengths of the RLDNon-Complex05/2027Newly added
Mitapivat SulfateOralTablet216196Minor Revision: Add information on newly approved strengths of the RLDNon-Complex02/2027Newly added
NabumetoneOralTablet019583Minor Revision: Add information on newly approved (lower or middle) strengths of the RLDNon-Complex05/2027Newly added
Naloxone HydrochlorideNasalSpray212045Minor Revision: Add information on newly approved (lower or middle) strengths of the RLDComplex02/2027Newly added
Olezarsen SodiumSubcutaneousSolution218614Minor Revision: Add information on newly approved (lower or middle) strengths of the RLDComplex02/2027Newly added
PaclitaxelIntravenousPowder216338Minor Revision: Add an in vitro BE optionComplex02/2027Newly added
PaclitaxelIntravenousPowder211875Minor Revision: Add an in vitro BE optionComplex02/2027Newly added
PaclitaxelIntravenousPowder021660Minor Revision: Add an in vitro BE option; Add information on newly approved (lower or middle) strengths approved by suitability petitionComplex02/2027Newly added
Pazopanib HydrochlorideOralTablet022465Minor Revision: Change in study design for in vivo BE studyNon-Complex05/2027No change
RisperidoneSubcutaneousFor suspension, extended release210655Minor Revision: Add an in vitro BE optionComplex02/2027No change
RisperidoneSubcutaneousSuspension, Extended release213586Minor Revision: Add an in vitro BE optionComplex02/2027No change
Selumetinib SulfateOralCapsule213756Major Revision: Add an in vivo fed BE studyNon-Complex02/2027Newly added
SemaglutideOralTablet213051

In Vivo Major Revision: Add an in vivo study; Remove recommendations for BE option

Minor Revision: Change in study design for in vivo BE study

Complex02/2027Newly added
SemaglutideOralTablet218316

In Vivo Major Revision: Add an in vivo study; Remove recommendations for BE option

Minor Revision: Change in study design for in vivo BE study

Complex02/2027Newly added
SemaglutideSubcutaneousSolution209637Minor Revision: Add recommendations for device comparisons; Add information on newly approved (lower or middle) strengths of the RLDComplex02/2027Newly added
SemaglutideSubcutaneousSolution215256Minor Revision: Add recommendations for device comparisons Editorial Revision: Reorganize to include all strengths within a single PSGComplex02/2027Newly added
TapentadolOralTablet022304Minor Revision: Add an in vitro BE optionNon-Complex02/2027Newly added
TestosteroneTransdermalGel021015Minor Revision: Add an in vitro BE option, clarify in vivo study design Editoiral Revision: Update the languageComplex02/2027No change
TestosteroneTransdermalGel, Metered021015Minor Revision: Add an in vitro BE option; Add recommendations for device comparisons; Clarify in vivo study design Editoiral Revision: Update the languageComplex02/2027No change
TestosteroneTransdermalGel, Metered021463Minor Revision: Add an in vitro BE option; add recommendations for device comparisons; clarify in vivo study design Editoiral Revision: Update the languageComplex02/2027No change
TestosteroneTransdermalGel022309Minor Revision: Add an in vitro BE option, clarify in vivo study design Editoiral Revision: Update the languageComplex02/2027No change
TestosteroneTransdermalGel, Metered022309Minor Revision: Add an in vitro BE option; add recommendations for device comparisons; clarify in vivo study design Editoiral Revision: Update the languageComplex02/2027No change
TestosteroneTransdermalGel021454Minor Revision: Add an in vitro BE option, clarify in vivo study design Editoiral Revision: Update the languageComplex02/2027No change

来源:FDA 官方药品与生物制品信息 · fda.gov